辛内福林 | 575-81-5

• 物质功能分类: 有机原料 - 酮类化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 辛内福林
• 中文别名: 辛佛宁；昔奈福林；2-正肾上腺素；辛内弗林；辛福林碱；交感醇；枳实提取物；辛弗林；对羟福林；1-(4-羟基苯基)-2-(甲基氨基)乙醇
• 英文名称: o-synephrine
• 英文别名: (+/-)-2-(1-hydroxy-2-methylamino-ethyl)-phenol；(+/-)-2-(1-Hydroxy-2-methylamino-aethyl)-phenol；1-(2-Hydroxy-phenyl)-2-methylamino-aethanol；2-[1-Hydroxy-2-(methylamino)ethyl]phenol
• CAS: 575-81-5
• 化学式: C₉H₁₃NO₂
• 分子量: 167.208
• InChiKey: YVGQHEIZCSVQHE-UHFFFAOYSA-N

物化性质

• 沸点：
  341.1±27.0 °C(Predicted)
• 密度：
  1.159±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  52.5
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  辛内福林 在 苯甲酰氯 、 溶剂黄146 作用下， 生成 (+)-2-(1-hydroxy-2-methylamino-ethyl)-phenol
  参考文献：
  名称：

  DE585164

  摘要：

  公开号：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 水 、 钯 作用下， 生成 辛内福林
  参考文献：
  名称：

  DE566578

  摘要：

  公开号：

文献信息

• Optically active fluorinated vasoconstrictors, methods for making them, and anesthetic formulations comprising them
  申请人：——

  公开号：US20040002549A1

  公开（公告）日：2004-01-01

  (R)-6F-phenylephrine, essentially free of (S)-6F-phenylephrine, and an anesthetic formulation comprising (R)-6F-epinephrin or (R)-6F-phenylephrine and having improved stability compared to formulations containing their non-fluorinated analog, are disclosed. Further disclosed is a method of providing vasoconstriction in a mammal by administering the anesthetic formulation. The anesthetic composition can include an anesthetic, an (R)-chiral compound having the structure: 1 wherein R 1 , R 2 , and R 4 are independently selected from —H or —F, at least one of R 1 , R 2 , and R 4 is —F, and R 3 is selected from —OH, —H or —F, or a pharmaceutically acceptable salt or ester thereof, said vasoconstrictor being essentially free of the (S)-chiral form. Also, a method of chiral addition of cyanide to a ring-fluorinated phenaldehyde, employing an almond hydroxynitrile lyase enzyme, provided in the form of a reversibly soluble polymer conjugate ((R)-Finezyme™-H series biocatalysts) is disclosed. Several such biocatalysts are disclosed.

  (R)-6F-苯肾上腺素，基本上不含(S)-6F-苯肾上腺素，并且包括(R)-6F-肾上腺素或(R)-6F-苯肾上腺素的麻醉制剂，其相比含有它们非氟化类似物的制剂具有改善的稳定性，已被披露。此外，还披露了通过给予哺乳动物麻醉制剂来提供血管收缩的方法。麻醉组合物可以包括麻醉剂、具有结构的(R)-手性化合物：其中R1、R2和R4独立地选择自—H或—F，R1、R2和R4中至少一个是—F，R3选择自—OH、—H或—F，或其药用可接受的盐或酯，所述血管收缩剂基本上不含(S)-手性形式。此外，还披露了一种利用杏仁羟基亚硝基酰酶酶将氰化物立体加到环氟化苯甲醛的方法，采用可逆溶解聚合物共轭形式提供(R)-Finezyme™-H系列生物催化剂。还披露了几种这样的生物催化剂。
• PROCESS FOR RESOLUTION OF 1-(3-HYDROXYPHENYL)-2-METHYLAMINO ETHANOL
  申请人：Divi Murali Krishna Prasad

  公开号：US20120108848A1

  公开（公告）日：2012-05-03

  Resolution of the title compound to its active isomer (R)-1-(3-hydroxyphenyl)-2-methylamino ethanol with (R)-naproxen as a resolving agent.

  将该化合物分辨到其活性异构体(R)-1-(3-羟基苯基)-2-甲氨基乙醇，使用(R)-萘普生作为分辨剂。
• Inhibitors of IMPDH enzyme
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP1964561A1

  公开（公告）日：2008-09-03

  The present invention relates to compounds which inhibit JMPDH. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting JMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH-mediated processes. This invention also relates to methods for inhibiting the activity of I1VIPDH using the compounds of this invention and related compounds.

  本发明涉及抑制 JMPDH 的化合物。本发明还涉及包含这些化合物的药物组合物。本发明的化合物和药物组合物特别适用于抑制 JMPDH 酶的活性，因此可作为 IMPDH 介导过程的治疗剂。本发明还涉及使用本发明化合物及相关化合物抑制 I1VIPDH 活性的方法。
• Method for treating a demyelinating condition
  申请人：——

  公开号：US20030055036A1

  公开（公告）日：2003-03-20

  Methods for treating a demyelinating condition in a subject in need of treatment are provided. In some aspects the methods encompass administering to the subject an amount of a Ca 2+ -channel blocker effective to treat the demyelinating condition. In other aspects, the methods encompass administering to the subject an amount of a glutamate inhibitor effective to treat the demyelinating condition. In additional aspects, the methods encompass administering to the subject a Ca 2+ -channel blocker in combination with a glutamate inhibitor, in amounts effective to treat the demyelinating condition. In still other aspects, the methods encompass administering to the subject a Ca 2+ -channel blocker in combination with a hypertensive agent, in amounts effective to treat the demyelinating condition. Also provided are pharmaceutical compositions having a Ca 2+ -channel blocker, a glutamate inhibitor, and a pharmaceutically-acceptable carrier. Additionally, pharmaceutical compositions having a Ca 2+ -channel blocker, a hypertensive agent, and a pharmaceutically-acceptable carrier are provided.

  本文提供了治疗需要治疗的受试者脱髓鞘病症的方法。在某些方面，这些方法包括向受试者施用一定量的 Ca 2&plus； -通道阻滞剂有效治疗脱髓鞘病症。在其他方面，这些方法包括向受试者施用有效治疗脱髓鞘病症的谷氨酸抑制剂。在其他方面，这些方法包括向受试者施用 Ca 2&plus； -通道阻滞剂与谷氨酸抑制剂联合使用，其用量对治疗脱髓鞘病症有效。还在其他方面，这些方法包括向受试者施用 Ca 2&plus； -通道阻滞剂与高血压药联合使用，其用量对治疗脱髓鞘病症有效。还提供了具有 Ca 2&plus； -通道阻滞剂、谷氨酸抑制剂和药学上可接受的载体的药物组合物。此外，还提供了具有 Ca 2&plus； -通道阻滞剂、高血压药和药学上可接受的载体的药物组合物。
• Fodor; Kovacs, Journal of the American Chemical Society, 1949, vol. 71, p. 1045,1047
  作者：Fodor、Kovacs

  DOI：——

  日期：——